Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine ER in Children and Adolescents With ADHD (Phase III, China)
CTR20221718Phase 3Completed
- Sponsor
- Shandong Bainuo Pharmaceutical
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of guanfacine in attention deficit hyperactivity disorder (ADHD), sponsored by Shandong Bainuo Pharmaceutical. Started Jul 2022; status: completed.
02
Drugs
guanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on CTR20221718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221718.